Cyclacel Pharmaceuticals, Inc. (CYCC) Financial Statements
Industry: Durable Goods (Other) (Wholesale)
In fiscal 2025, Cyclacel Pharmaceuticals reported revenue of $0, down 100.0% from $43,000 the year before. Net income was -$3.0M, or -$6.45 per diluted share. Operating activities generated -$4.8M of cash. At fiscal year end, Cyclacel Pharmaceuticals held $8.2M in total assets against $1.3M in total liabilities, including $3.5M of cash and equivalents.
Open the full interactive Cyclacel Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Cyclacel Pharmaceuticals Key Stats
| Share Price | $0.92 |
|---|---|
| Market Cap | $5.2M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $0.60 – $5.95 |
| Shares Outstanding | 5.6 million (basic, 2026 Q2) |
Cyclacel Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $420,000 | $43,000 | $0 |
| Operating Income | -$10.6M | -$22.9M | -$27.7M | -$25.5M | -$12.0M | -$8.4M |
| Pre-Tax Income | -$9.7M | -$22.7M | -$25.9M | -$25.6M | -$12.0M | -$3.0M |
| Income Tax | -$1.2M | -$3.8M | -$4.7M | -$3.0M | -$782,000 | $7,000 |
| Net Income | -$8.4M | -$18.9M | -$21.2M | -$22.6M | -$11.2M | -$3.0M |
| Diluted EPS | -$12312.00 | -$7704.00 | -$6840.00 | — | -$501.60 | -$6.45 |
Cyclacel Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $81,000 | — | $743,000 | $336,000 |
| Net Income | -$988,000 | -$611,000 | -$197,000 | -$405,000 |
| Diluted EPS | -$1.31 | -$0.28 | -$0.04 | -$0.07 |
Cyclacel Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.4M | $36.6M | $18.3M | $3.4M | $3.1M | $3.5M |
| Current Assets | $35.5M | $40.9M | $24.4M | $7.4M | $3.7M | $6.3M |
| Total Assets | $36.8M | $42.6M | $27.5M | $8.8M | $4.1M | $8.2M |
| Current Liabilities | $2.5M | $5.3M | $7.4M | $8.2M | $6.3M | $1.3M |
| Total Liabilities | $3.5M | $5.3M | $7.5M | $8.2M | $6.3M | $1.3M |
| Shareholders' Equity | $33.3M | $37.3M | $15.5M | $607,000 | -$2.2M | $6.8M |
Cyclacel Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$7.9M | -$18.5M | -$20.8M | -$16.1M | -$8.0M | -$4.8M |
| Cash From Investing | -$96,000 | -$27,000 | -$7,000 | -$6,000 | — | — |
| Cash From Financing | $29.5M | $21.7M | $3.0M | $848,000 | $7.8M | $5.3M |
| Free Cash Flow | -$8.0M | -$18.6M | -$20.8M | -$16.1M | -$8.0M | — |
Figures from Cyclacel Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cyclacel Pharmaceuticals financials page for every line item.
Cyclacel Pharmaceuticals Company Profile
| Ticker | CYCC |
|---|---|
| Exchange | Nasdaq, OTC |
| Industry | Durable Goods (Other) (Wholesale) |
| Headquarters | Berkeley Heights, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001130166 |
Frequently Asked Questions
What was Cyclacel Pharmaceuticals' revenue in fiscal 2025?
Cyclacel Pharmaceuticals (CYCC) reported revenue of $0 for fiscal 2025.
What is Cyclacel Pharmaceuticals' annual revenue history?
Cyclacel Pharmaceuticals' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $420,000; 2024: $43,000; 2025: $0.
What was Cyclacel Pharmaceuticals' net income in fiscal 2025?
Cyclacel Pharmaceuticals reported net income of -$3.0M for fiscal 2025.
What was Cyclacel Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Cyclacel Pharmaceuticals' diluted EPS was -$6.45 for fiscal 2025 (adjusted for any later stock splits).
What was Cyclacel Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cyclacel Pharmaceuticals reported revenue of $336,000.
How many shares of Cyclacel Pharmaceuticals are outstanding?
Cyclacel Pharmaceuticals reported a weighted average of 5.6 million basic shares outstanding in 2026 Q2.
What is Cyclacel Pharmaceuticals' market cap?
Based on its latest closing price, Cyclacel Pharmaceuticals (CYCC) has a market capitalization of about $5.2M.
When does Cyclacel Pharmaceuticals' fiscal year end?
Cyclacel Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Cyclacel Pharmaceuticals headquartered?
Cyclacel Pharmaceuticals lists its business address in Berkeley Heights, New Jersey in its SEC filings.